Possible mechanisms of action of mushroom-derived glucans on inflammatory bowel disease and associated cancer

Annals of Translational Medicine

Volumn 2, Issue 2, 2014, Pages

  Schwartz, Betty ^a   Hadar, Yitzhak ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Colon cancer; Inflammation; Inflammatory bowel disease (IBD); glucans; glucans

Indexed keywords

EID: 85015500535     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.3978/j.issn.2305-5839.2014.01.03     Document Type: Article

References (82)

1. Wong BW, Meredith A, Lin D, et al. The biological role of inflammation in atherosclerosis. Can J Cardiol 2012;28:631-41.
2. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-96.
3. Atsumi T, Singh R, Sabharwal L, et al. Inflammation amplifier, a new paradigm in cancer biology. Cancer Res 2014;74:8-14.
4. Cader MZ, Kaser A. Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut 2013;62:1653-64.
5. Burisch J, Munkholm P. Inflammatory bowel disease epidemiology. Curr Opin Gastroenterol 2013;29:357-62.
6. Nguyen GC, Chong CA, Chong RY. National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States. J Crohns Colitis 2013. [Epub ahead of print].
7. Kemp R, Dunn E, Schultz M. Immunomodulators in inflammatory bowel disease: an emerging role for biologic agents. BioDrugs 2013;27:585-90.
8. Monteleone G, Caruso R, Pallone F. Targets for new immunomodulation strategies in inflammatory bowel disease. Autoimmun Rev 2014;13:11-4.
9. Brazil JC, Louis NA, Parkos CA. The role of polymorphonuclear leukocyte trafficking in the perpetuation of inflammation during inflammatory bowel disease. Inflamm Bowel Dis 2013;19:1556-65.
10. Moriconi F, Raddatz D, Ho NA, et al. Quantitative gene expression of cytokines in peripheral blood leukocytes stimulated in vitro: modulation by the anti-tumor nerosis factor-alpha antibody infliximab and comparison with the mucosal cytokine expression in patients with ulcerative colitis. Transl Res 2007;150:223-32.
11. Biesiada G, Czepiel J, Ptak-Belowska A, et al. Expression and release of leptin and proinflammatory cytokines in patients with ulcerative colitis and infectious diarrhea. J Physiol Pharmacol 2012;63:471-81.
12. Billiet T, Rutgeerts P, Ferrante M, et al. Targeting TNF-alpha for the treatment of inflammatory bowel disease. Expert Opin Biol Ther 2014;14:75-101.
13. Peyrin-Biroulet L. Anti-TNF therapy in inflammatory bowel diseases: a huge review. Minerva Gastroenterol Dietol 2010;56:233-43.
14. Shepela C. The safety of biologic agents in the treatment of inflammatory bowel disease. Minn Med 2008;91:42-5.
15. Yehuda-Shnaidman E, Schwartz B. Mechanisms linking obesity, inflammation and altered metabolism to colon carcinogenesis. Obes Rev 2012;13:1083-95.
16. Viennois E, Chen F, Merlin D. NF-kappaB pathway in colitis-associated cancers. Transl Gastrointest Cancer 2013;2:21-9.
17. Monteleone G, Pallone F, StolfiC. The dual role of inflammation in colon carcinogenesis. Int J Mol Sci 2012;13:11071-84.
18. Dyson JK, Rutter MD. Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? World J Gastroenterol 2012;18:3839-48.
19. Ganeshpurkar A, Rai G. Experimental evaluation of analgesic and anti-inflammatory potential of Oyster mushroom Pleurotus florida. Indian J Pharmacol 2013;45:66-70.
20. Alves MJ, Ferreira IC, Dias J, et al. A review on antifungal activity of mushroom (basidiomycetes) extracts and isolated compounds. Curr Top Med Chem 2013;13:2648-59.
21. Mizuno M, Nishitani Y. Immunomodulating compounds in Basidiomycetes. J Clin Biochem Nutr 2013;52:202-7.
22. Ren L, Perera C, Hemar Y. Antitumor activity of mushroom polysaccharides: a review. Food Funct 2012;3:1118-30.
23. Wasser SP. Current findings, future trends, and unsolved problems in studies of medicinal mushrooms. Appl Microbiol Biotechnol 2011;89:1323-32.
24. Lima LF, Habu S, Gern JC, et al. Production and characterization of the exopolysaccharides produced by Agaricus brasiliensis in submerged fermentation. Appl Biochem Biotechnol 2008;151:283-94.
25. Wasser SP. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol 2002;60:258-74.
26. Lavi I, Levinson D, Peri I, et al. Chemical characterization, antiproliferative and antiadhesive properties of polysaccharides extracted from Pleurotus pulmonarius mycelium and fruiting bodies. Appl Microbiol Biotechnol 2010;85:1977-90.
27. Smiderle FR, Sassaki GL, van Arkel J, et al. High molecular weight glucan of the culinary medicinal mushroom Agaricus bisporus is an alpha-glucan that forms complexes with low molecular weight galactan. Molecules 2010;15:5818-30.
28. Papagianni M. Fungal morphology and metabolite production in submerged mycelial processes. Biotechnol Adv 2004;22:189-259.
29. Brown GD, Gordon S. Fungal beta-glucans and mammalian immunity. Immunity 2003;19:311-5.
30. Brown GD, Gordon S. Immune recognition of fungal beta-glucans. Cell Microbiol 2005;7:471-9.
31. Zekovic DB, Kwiatkowski S, Vrvic MM, et al. Natural and modified (1→3)-beta-D-glucans in health promotion and disease alleviation. Crit Rev Biotechnol 2005;25:205-30.
32. Rice PJ, Adams EL, Ozment-Skelton T, et al. Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge. J Pharmacol Exp Ther 2005;314:1079-86.
33. Wu D, Han SN, Bronson RT, et al. Dietary supplementation with mushroom-derived protein-bound glucan does not enhance immune function in young and old mice. J Nutr 1998;128:193-7.
34. Bedirli A, Kerem M, Pasaoglu H, et al. Beta-glucan attenuates inflammatory cytokine release and prevents acute lung injury in an experimental model of sepsis. Shock 2007;27:397-401.
35. Volman JJ, Ramakers JD, Plat J. Dietary modulation of immune function by beta-glucans. Physiol Behav 2008;94:276-84.
36. Chan GC, Chan WK, Sze DM. The effects of beta-glucan on human immune and cancer cells. J Hematol Oncol 2009;2:25.
37. Lavi I, Levinson D, Peri I, et al. Orally administered glucans from the edible mushroom Pleurotus pulmonarius reduce acute inflammation in dextran sulfate sodium-induced experimental colitis. Br J Nutr 2010;103:393-402.
38. Nosál'ová V, Bobek P, Cerna S, et al. Effects of pleuran (beta-glucan isolated from Pleurotus ostreatus) on experimental colitis in rats. Physiol Res 2001;50:575-81.
39. Lavi I, Nimri L, Levinson D, et al. Glucans from the edible mushroom Pleurotus pulmonarius inhibit colitis-associated colon carcinogenesis in mice. J Gastroenterol 2012;47:504-18.
40. Choi SY, Hur SJ, An CS, et al. Anti-inflammatory effects of Inonotus obliquus in colitis induced by dextran sodium sulfate. J Biomed Biotechnol 2010;2010:943516.
41. Kim YO, Park HW, Kim JH, et al. Anti-cancer effect and structural characterization of endo-polysaccharide from cultivated mycelia of Inonotus obliquus. Life Sci 2006;79:72-80.
42. Goodridge HS, Wolf AJ, Underhill DM. Beta-glucan recognition by the innate immune system. Immunol Rev 2009;230:38-50.
43. Thornton BP, Vetvicka V, Pitman M, et al. Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol 1996;156:1235-46.
44. Xie J. The C-type lectin-like receptors of Dectin-1 cluster in natural killer gene complex. Glycoconj J 2012;29:273-84.
45. Sun L, Zhao Y. The biological role of dectin-1 in immune response. Int Rev Immunol 2007;26:349-64.
46. Willment JA, Gordon S, Brown GD. Characterization of the human beta-glucan receptor and its alternatively spliced isoforms. J Biol Chem 2001;276:43818-23.
47. Ariizumi K, Shen GL, Shikano S, et al. Identification of a novel, dendritic cell-associated molecule, dectin-1, by subtractive cDNA cloning. J Biol Chem 2000;275:20157-67.
48. Adachi Y, Ishii T, Ikeda Y, et al. Characterization of beta-glucan recognition site on C-type lectin, dectin 1. Infect Immun 2004;72:4159-71.
49. Palma AS, Feizi T, Zhang Y, et al. Ligands for the beta-glucan receptor, Dectin-1, assigned using "designer" microarrays of oligosaccharide probes (neoglycolipids) generated from glucan polysaccharides. J Biol Chem 2006;281:5771-9.
50. Underhill DM, Rossnagle E, Lowell CA, et al. Dectin-1 activates Syk tyrosine kinase in a dynamic subset of macrophages for reactive oxygen production. Blood 2005;106:2543-50.
51. Underhill DM. Collaboration between the innate immune receptors dectin-1, TLRs, and Nods. Immunol Rev 2007;219:75-87.
52. García-Lora A, Martinez M, Pedrinaci S, et al. Different regulation of PKC isoenzymes and MAPK by PSK and IL-2 in the proliferative and cytotoxic activities of the NKL human natural killer cell line. Cancer Immunol Immunother 2003;52:59-64.
53. García-Lora A, Pedrinaci S, Garrido F. Protein-bound polysaccharide K and interleukin-2 regulate different nuclear transcription factors in the NKL human natural killer cell line. Cancer Immunol Immunother 2001;50:191-8.
54. Hong F, Yan J, Baran JT, et al. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol 2004;173:797-806.
55. Xia Y, Vetvicka V, Yan J, et al. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J Immunol 1999;162:2281-90.
56. Berner MD, Sura ME, Alves BN, et al. IFN-gamma primes macrophages for enhanced TNF-alpha expression in response to stimulatory and non-stimulatory amounts of microparticulate beta-glucan. Immunol Lett 2005;98:115-22.
57. Ito K, Nakazato H, Koike A, et al. Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up. Int J Colorectal Dis 2004;19:157-64.
58. Ohwada S, Ikeya T, Yokomori T, et al. Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. Br J Cancer 2004;90:1003-10.
59. Aleem E. beta-Glucans and their applications in cancer therapy: focus on human studies. Anticancer Agents Med Chem 2013;13:709-19.
60. Peyrin-Biroulet L, Lepage C, Jooste V, et al. Colorectal cancer in inflammatory bowel diseases: a population-based study (1976-2008). Inflamm Bowel Dis 2012;18:2247-51.
61. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012;10:639-45.
62. Rogler G. Chronic ulcerative colitis and colorectal cancer. Cancer Lett 2013. [Epub ahead of print].
63. Chen B, She S, Li D, et al. Role of miR-19a targeting TNF-alpha in mediating ulcerative colitis. Scand J Gastroenterol 2013;48:815-24.
64. Førland DT, Johnson E, Saetre L, et al. Effect of an extract based on the medicinal mushroom Agaricus blazei Murill on expression of cytokines and calprotectin in patients with ulcerative colitis and Crohn's disease. Scand J Immunol 2011;73:66-75.
65. Okamoto T, Kodoi R, Nonaka Y, et al. Lentinan from shiitake mushroom (Lentinus edodes) suppresses expression of cytochrome P450 1A subfamily in the mouse liver. Biofactors 2004;21:407-9.
66. Lifshitz S, Schwartz B, Polak-Charcon S, et al. Extensive apoptotic death of rat colonic cells deprived of crypt habitat. J Cell Physiol 1998;177:377-86.
67. Lifshitz S, Lamprecht SA, Benharroch D, et al. Apoptosis (programmed cell death) in colonic cells: from normal to transformed stage. Cancer Lett 2001;163:229-38.
68. Chen W, Zhao Z, Chen SF, et al. Optimization for the production of exopolysaccharide from Fomes fomentarius in submerged culture and its antitumor effect in vitro. Bioresour Technol 2008;99:3187-94.
69. Xie JT, Wang CZ, Wicks S, et al. Ganoderma lucidum extract inhibits proliferation of SW 480 human colorectal cancer cells. Exp Oncol 2006;28:25-9.
70. Lavi I, Friesem D, Geresh S, et al. An aqueous polysaccharide extract from the edible mushroom Pleurotus ostreatus induces anti-proliferative and pro-apoptotic effects on HT-29 colon cancer cells. Cancer Lett 2006;244:61-70.
71. Kobayashi H, Yoshida R, Kanada Y, et al. Suppressing effects of daily oral supplementation of beta-glucan extracted from Agaricus blazei Murill on spontaneous and peritoneal disseminated metastasis in mouse model. J Cancer Res Clin Oncol 2005;131:527-38.
72. Shanmugam MK, Kannaiyan R, Sethi G. Targeting cell signaling and apoptotic pathways by dietary agents: role in the prevention and treatment of cancer. Nutr Cancer 2011;63:161-73.
73. Hu H, Zhang Z, Lei Z, et al. Comparative study of antioxidant activity and antiproliferative effect of hot water and ethanol extracts from the mushroom Inonotus obliquus. J Biosci Bioeng 2009;107:42-8.
74. Zhang M, Chiu LC, Cheung PC, et al. Growth-inhibitory effects of a beta-glucan from the mycelium of Poria cocos on human breast carcinoma MCF-7 cells: cell-cycle arrest and apoptosis induction. Oncol Rep 2006;15:637-43.
75. Gown AM, Willingham MC. Improved detection of apoptotic cells in archival paraffin sections: immunohistochemistry using antibodies to cleaved caspase 3. J Histochem Cytochem 2002;50:449-54.
76. Jakob S, Corazza N, Diamantis E, et al. Detection of apoptosis in vivo using antibodies against caspase-induced neo-epitopes. Methods 2008;44:255-61.
77. Joo YE, Karrasch T, Muhlbauer M, et al. Tomato lycopene extract prevents lipopolysaccharide-induced NF-kappaB signaling but worsens dextran sulfate sodium-induced colitis in NF-kappaBEGFP mice. PLoS One 2009;4:e4562.
78. Paul G, Bataille F, Obermeier F, et al. Analysis of intestinal haem-oxygenase-1 (HO-1) in clinical and experimental colitis. Clin Exp Immunol 2005;140:547-55.
79. Murphy EA, Davis JM, Carmichael MD. Immune modulating effects of beta-glucan. Curr Opin Clin Nutr Metab Care 2010;13:656-61.
80. Shimizu K, Watanabe S, Matsuda K, et al. Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer. Hepatogastroenterology 2009;56:240-4.
81. Hazama S, Watanabe S, Ohashi M, et al. Efficacy of orally administered superfine dispersed lentinan (beta-1,3-glucan) for the treatment of advanced colorectal cancer. Anticancer Res 2009;29:2611-7.
82. Isoda N, Eguchi Y, Nukaya H, et al. Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma. Hepatogastroenterology 2009;56:437-41.